New Delhi, Nov. 28 -- Russia's sovereign wealth fund and the Hyderabad-based Hetero Biopharma, engaged in manufacturing generic medicines have inked a pact to produce more than 100 million doses per year in India of the Sputnik V vaccine.
The Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plans to start production at the beginning of 2021.
Sputnik V is based on a well-studied platform of human adenoviral vectors and has demonstrated a 91.4 percent efficacy rate, according to the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers. The results were announced by Gamaleya Center and RDIF o...